News & Updates

The serine protease inhibitor upamostat appears to be beneficial in the treatment of COVID-19 outpatients, being generally tolerable and bringing a rapid resolution of severe symptoms while reducing the incidence of new ones, according to the results of a pilot study.

Weekly bepirovirsen treatment may help reduce HBsAg* and hepatitis B virus (HBV) DNA levels in patients with chronic HBV infection, the phase IIb B-Clear study showed.

One in every eight individuals who has experienced COVID-19 may have persistent symptoms 3–5 months post-infection, according to an observational study from the Netherlands.

Individuals who have received one or two doses of the COVID-19 vaccinations experience improved mental wellbeing during the pandemic, reports a recent Japan study.

Pregnant or recently pregnant women who needed intensive care admission due to COVID-19 tend to live in poorer areas and are less likely to have been vaccinated, a recent study has found.

Evidence for excess risk and increased burden of new-onset diabetes among COVID-19 survivors is robust, and most antihyperglycaemic drugs can be used safely during acute COVID-19, with some drugs potentially offering protection against serious complications, according to data presented at 5^th EDM HK.

A few paediatric renal transplant recipients who presented with suspected infection within 2 years of transplant were diagnosed with bacteraemia or urinary tract infections (UTIs) or both, reports a study. Evaluations are highly variable, with a third of visits without urine cultures obtained.